As per the latest market research conducted by FMI, the global Microneedle Drug Delivery Systems Market is expected to record a CAGR of 6.6% from 2023 to 2033. In 2023, the market size is projected to reach a valuation of USD 768.9 million. By 2033, the valuation is anticipated to reach USD 1459.1 million.
In order to administer enough doses of medication to have the desired therapeutic effect, hundreds of microneedles are arranged in arrays on a small patch. As a result, there is now a direct route for a medication to enter the viable epidermis without coming into contact with the nerves and blood vessels found in the dermal layers.
Depending on their qualities, numerous types of materials, including ceramic, silicon, silica glass, carbohydrates, and polymers, are utilized to make microneedles, thus driving the microneedling tool market in the coming years. Typically, microneedles measure hundreds of microns in length, 1 to 50 micrometers in width at the tip, and 50 to 300 micrometers in length at the base.
Significant Market Trends:
| Attributes | Value |
|---|---|
| Microneedle Drug Delivery Systems Value (2022) | USD 722.2 million |
| Microneedle Drug Delivery Systems Market Expected Value (2023) | USD 768.9 million |
| Microneedle Drug Delivery Systems Market Forecast Value (2033) | USD 1459.1 million |
| Microneedle Drug Delivery Systems Market Expected CAGR (2023 to 2033) | 6.6% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Nevertheless, constraints to market expansion are anticipated to include high costs associated with research and development capabilities, a lack of adequate infrastructure, unequal access to medical services, growing interest in alternative drug delivery methods like transdermal and intradermal systems, and a lack of awareness in developing nations.
Besides, it is anticipated that the absence of a favorable reimbursement scenario, a lack of technology penetration in developing economies, poor absorption and variation in absorption, a lack of adequate infrastructure in low- and middle-income groups, limited insurance coverage, and a lack of regulatory compliance is anticipated to pose challenges to the market during the forecast period.
The emergence of safer substitutes for traditional hypodermic injections is the main factor behind the expansion of microneedle drug delivery systems.
The popularity of safety concerns is another primary trend boosting the development of microneedle drug delivery systems.
The launch of a new microneedle patch is expected to make it simpler to vaccinate people in the event of preventable diseases as percenters for disease control and prevention.
Consequently, the need for microneedle drug delivery systems is increasing as a result of vaccines against numerous diseases like measles.
Besides this, the microneedle patch can be given by medical professionals with little training.
The most significant factor driving the market for microneedle drug delivery systems is the high adoption of emerging safety issues that have short- and long-term implications for clinicians, patients, health workers, and regulators, growing research and development measures, and increasing demands for a safer alternative to traditional hypodermic injections.
Principal Consultant
According to the WHO, new instances of cancer are anticipated to increase by roughly 70% over the following 20 years, which may lead to a need for microneedle patches as a drug delivery method.
The market for microneedle drug delivery systems is expected to be driven by advances in technology like microneedle patches and an increase in transdermal drug delivery applications for pain treatment, congestive heart failure, and hormone replacement.
The market expansion for microneedle drug delivery systems is anticipated to be hampered by drug degradation, local discomfort, poor absorption, and variability in absorption.
The Centers for Disease Control and Prevention claim that a new microneedle patch might make it simpler to immunize people against measles and other diseases that can be prevented by vaccination.
Due to the highly contagious nature of the measles virus, measures should be taken throughout the production and administration of the vaccine. Every year, measles affects over 25 million people, and sadly, the global measles vaccination rate has been hovering around 85% for the past few years, which is below the target level.
| Particulars | Details |
|---|---|
| H1, 2021 | 6.46% |
| H1, 2022 Projected | 6.60% |
| H1, 2022 Outlook | 6.10% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 50 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 36 ↓ |
The comparative analysis and market growth rate of the global microneedle drug delivery systems market as studied by Future Market Insights shows a negative BPS growth in the H1-2022 outlook as compared to H1-2022 projected period by 50 BPS, and, a decline in the BPS growth is expected in H1-2022 over H1- 2021 duration with 36 basis point share (BPS).
The expensive costs of creating a reproducible microneedle patch as well as the high expenses of storing and packaging microneedles for safe distribution are also factors that have been cited as limiting the decline in BPS levels.
The market is expected to gain momentum towards expansion over the anticipated years thanks to the advantages of microneedles in advanced transdermal drug administration, including enhanced bioavailability of pharmaceuticals, reduced side effects, and rapid beginning of therapeutic action.
The introduction of solid, dissolving, and coated microneedles for efficient transdermal drug administration is one of the market's major advances. With regard to medication safety and product licensing operations, the market for microneedle drug delivery systems is subject to changes based on regulatory and industry dynamics.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The Demand for Microneedles for Drug Delivery is Being Driven by an Increase in Cancer Patients
The demand for innovative and efficient drug delivery methods to enhance therapy is being driven by the rising prevalence of chronic diseases in the United States, including diabetes and cancer. As a result, businesses and research organizations are bringing new product development to the nation, establishing it as a profitable segment.
In 2022, the United States witnessed 1.9 million new cancer cases diagnosed and 609,360 cancer deaths, according to Cancer Facts & Figures (2022), an educational companion to Cancer Statistics (2022), an article published in the American Cancer Society journal.
This is expected to encourage the development of new oncology treatments, driving the market for microneedle drug delivery systems in the country.
Demand for High-Quality Drugs & Access to Low-Cost Raw Ingredients Allows China to Expand its Industry
China is anticipated to hold a significant position in the East Asia market over the projection period. China's government organizations are investing more money in developing the healthcare industry, which is fostering the production of novel pharmaceuticals therein.
Several international pharmaceutical companies are looking to expand their operations in China due to the abundance of low-cost raw materials and the increased demand for generic medicines.
| Country | United States |
|---|---|
| CAGR (2018 to 2022) | 5.1% |
| CAGR (2023 to 2033) | 5.7% |
| Valuation (2033) | USD 528.6 million |
| Country | United Kingdom |
|---|---|
| CAGR (2018 to 2022) | 6.4% |
| CAGR (2023 to 2033) | 7.0% |
| Valuation (2033) | USD 84.4 million |
| Country | China |
|---|---|
| CAGR (2018 to 2022) | 5.7% |
| CAGR (2023 to 2033) | 6.2% |
| Valuation (2033) | USD 77.1 million |
| Country | Germany |
|---|---|
| CAGR (2018 to 2022) | 4.7% |
| CAGR (2023 to 2033) | 5.1% |
| Valuation (2033) | USD 79.3 million |
Solid Microneedles Dominate the Development of Microneedle Drug Delivery Devices
Solid microneedles remain the market leader despite a slight decline in market share during the anticipated time frame.
They are anticipated to have covered more than 50% of the market by the end of 2033. In the meantime, hollow and dissolving microneedles are anticipated to proliferate more quickly with the usage of new technologies and uses.
Research on solid microneedles is now being conducted for several applications in an effort to increase their consistency, stability, and affordability. At the moment, research is concentrated on the creation of a microneedle array.
Hospitals Set to Account for Higher Consumption of Microneedles for Drug Delivery
In 2022, hospitals held a top position as end users, accounting for 44.1% of the global market. The expansion of the worldwide microneedle drug delivery systems market is anticipated to be aided by specialty clinics.
Specialty clinics held a 22% market share globally in 2022. As more clinics focus on particular disorders, the market potential is anticipated to rise in the future.
For instance, one of the biggest consumers of microneedle drug delivery devices for procedures like hair restoration, facelifts, and wrinkle therapy are cosmetic clinics. Which is expected to eventually drive the microneedling for hair loss market.
The global microneedle drug delivery systems market is dominated by large- and medium-sized companies. However, it is led by a few important companies that, as part of their marketing strategy, are focusing on their market and value chain positions.
Prominent market players use a range of tactics, such as early market entry, deep market penetration, as well as exclusive marketing and distribution licensing. Product innovation and differentiation, however, are essential market strategies for both mid-size and large businesses due to the diversity of market players.
Regardless of their size, companies use distribution rights acquisition and exclusive technology licensing as core strategies. In particular, a few businesses are focusing on strategic alliances in order to get a competitive edge.
Leading companies that sell microneedle drug delivery equipment are concentrating on Research and Development to introduce cutting-edge items in the market. In order to obtain a competitive edge in the market, firms are also engaging in mergers, acquisitions, and collaborations.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | USD million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia & Pacific; Middle East & Africa (MEA) |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, China, Japan, South Korea, India, Indonesia, Malaysia, Singapore, Australia, New Zealand, Türkiye, South Africa, GCC Countries |
| Key Market Segments Covered | Product, End User, Region |
| Key Companies Profiled | 3M Company; Becton; Dickinson and Company; Zosano Pharma Corporation; Raphas Co. Ltd.; Nanopass Tech; Corium International Inc.; Valeritas Inc.; Nitto Denko Corporation; Microdermics Inc.; TheraJect Inc.; Vaxxas Pty Ltd.; Endoderma Ltd.; QuadMedicine; SNvia Co. Ltd.; Small Lab; AdminMed nanoBioSciences LLC |
| Pricing | Available upon Request |
The market may register a revenue of USD 768.9 million in 2023.
The United States is the leading country in the market.
China is the leading market and is expected to grow at 6.2% until 2033.
The solid microneedle segment dominates and could hold 50% of the global market by 2033.
The hospitals segment accounted the top position with 44.1% market share in 2022.
1. Executive Summary | Microneedle Drug Delivery Systems Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 5.1. Solid Microneedles 5.1.1. Silicon 5.1.2. Metal 5.1.3. Polymer 5.2. Hollow Microneedles 5.3. Dissolving Microneedles 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Use 6.1. Hospitals 6.2. Ambulatory Surgical Centers 6.3. Specialty Clinics 6.4. Academic Institutions 6.5. Research Institutes 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. South Asia 7.5. East Asia 7.6. Oceania 7.7. Middle East and Africa 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1.1. 3M Company 17.1.2. Becton, Dickinson and Company 17.1.3. Zosano Pharma Corporation 17.1.4. RAPHAS Co., Ltd. 17.1.5. Nanopass Tech 17.1.6. Corium International, Inc. 17.1.7. Valeritas, Inc. 17.1.8. Nitto Denko Corporation 17.1.9. Microdermics, Inc. 17.1.10. TheraJect Inc. 17.1.11. Vaxxas Pty Ltd. 17.1.12. Endoderma Ltd. 17.1.13. QuadMedicine 17.1.14. SNvia Co., Ltd. 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Microneedle Drug Delivery Systems Market
